Screening of potential anti-Trypanosoma cruzi candidates: In Vitro and In Vivo studies

Open Medicinal Chemistry Journal

Volumn 5, Issue SPEC. ISSUE 1, 2011, Pages 21-30

  Soeiro, Maria de Nazaré C ^a   de Castro, Solange Lisboa ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Aromatic diamidines; Chagas disease; Experimental chemotherapy; Megazol derivatives; Naphthoquinones; Trypanosoma cruzi

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 2,3 DIHYDRO 2 IODOMETHYLENE 4,5 DIOXO NAPHTHO[1,2 B]FURAN; 2,3 DIHYDRO 2 IODOMETHYLENE 4,9 DIOXONAPHTHO[2,3 B]FURAN; 2,3 DIHYDRO 2 METHYL 4,5 DIOXO NAPHTHO[1,2 B]FURAN; 2,5 BIS(4 AMIDINOPHENYL)FURAN; 3 (3 NITROPHENYLAMINO) 2,3 DIHYDRO 2,2 DIMETHYLNAPHTHO[1,2 B]FURAN 4,5 DIONE; 3 (4 METHOXYPHENYLAMINO) 2,3 DIHYDRO 2,2 DIMETHYLNAPHTHO[1,2 B]FURAN 4,5 DIONE; 3,4 DIHYDROXYBENZYLIDENE [5 (1 METHYL 5 NITRO 1H IMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL]HYDRAZINE; 4 BROMOBENZYLIDENE [5 (1 METHYL 5 NITRO 1H IMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL]HYDRAZINE; 4 HYDROXYBENZYLIDENE [5 (1 METHYL 5 NITRO 1H IMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL]HYDRAZINE; 4 NITROBENZYLIDENE [5 (1 METHYL 5 NITRO 1H IMIDAZOL 2 YL) 1,3,4 THIADIAZOL 2 YL]HYDRAZINE; 4,5 DIHYDRO 6,6 DIMETHYL 6H 2 (3' INDOLYL)PYRAN[B 4,3]NAPHTH[1,2 D]IMIDAZOLE; 4,5 DIHYDRO 6,6 DIMETHYL 6H 2 (4' METHYLPHENYL)PYRAN[B 4,3]NAPHTH[1,2 D]IMIDAZOLE; 4,5 DIHYDRO 6,6 DIMETHYL 6H 2 (PHENYL)PYRAN[B 4,3]NAPHTH[1,2 D]IMIDAZOLE; AMIDINE; ANTITRYPANOSOMAL AGENT; DB 1362; DB 1582; DB 1627; DB 1645; DB 1646; DB 1651; DB 1670; DB 569; DB 613A; DB 702; DB 889; DIAMIDINE DERIVATIVE; PAFURAMIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIPROTOZOAL ACTIVITY; CHAGAS DISEASE; DRUG DETERMINATION; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; NONHUMAN; PARASITE SURVIVAL; PARASITE VIRULENCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

EID: 80455174227     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501105010021     Document Type: Review

References (105)

1. Dias, J.C.P. Elimination of Chagas disease transmission: perspectives. Mem. Inst. Oswaldo Cruz, 2009, 104 (Suppl. I), 41-5.
2. Brener, Z.; Andrade, Z.; Barral-Netto, M. Trypanosoma cruzi e doença de Chagas. Guanabara Koogan: Rio de Janeiro, 1999, 431 p.
3. Dias, J.C.P. Globalization, inequity and Chagas disease. Cad. Saúde Pública, 2007, 23 Suppl, S13-22.
4. Herwaldt, B.L. Laboratory-acquired parasitic infections from accidental exposures. Clin. Microbiol. Rev., 2001, 14, 659-88.
5. Atclas, J.D.; Barcan, L.; Nagel, C.; Lattes, R.; Riarte, A. Organ transplantation and Chagas disease. JAMA, 2008, 299, 134-5.
6. Steindel, M.; Kramer Pacheco, L.; Scholl, D.; Soares, M.; Moraes, M.H.; Eger, I.; Kosmann, C.; Sincero, T.C.; Stoco, P.H.; Murta, S.M.; de Carvalho-Pinto, C.J.; Grisard, E.C. Characterization of Trypanosoma cruzi isolated from humans, vectors, and animal reservoirs following an outbreak of acute human Chagas disease in Santa Catarina State, Brazil. Diagn. Microbiol. Infect. Dis., 2008, 60, 25-32.
7. Vaidian, A.K.; Weiss, L.M.; Tanowitz, H.B. Chagas' disease and AIDS. Kinetoplastid Biol. Dis., 2004, 3, 2.
8. Schmunis, G.A. Epidemiology of Chagas disease in non endemic countries: the role of international migration. Mem. Inst. Oswaldo Cruz, 2007, 102 (Suppl 1), 75-85.
9. Coura, J.R. Chagas disease: what is known and what is needed - A background article. Mem. Inst. Oswaldo Cruz, 2007,102, 113-22.
10. Duschak, V.G.; Couto, A.S. An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Pat. Antiinfect. Drug Discov., 2007, 2, 19-51.
11. McKerrow, J.H.; Doyle, P.S.; Engel, J.C.; Podust, L.M.; Robertson, S.A.; Ferreira, R.; Saxton, T.; Arkin, M.; Kerr, I.D.; Brinen, L.S.; Craik, C.S. Two approaches to discovering and developing new drugs for Chagas disease Mem. Inst. Oswaldo Cruz, 2009, 104 (Suppl. I), 263-9.
12. Urbina, J.A. Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo Cruz, 2009, 104 (Suppl. I), 311-8.
13. Soeiro, M.N.C.; Dailyri, A.; Silva, C.F.; Batista, D.G.J.; De Souza, E.M.; Oliveira, G.M.; Salomão, K.; Batista, M.M.; Pacheco, M.; Silva, P.B.; Santa-Rita, R.M.; Menna-Barreto, R.F.S.; Boykin, D.W.; De Castro, S.L. Experimental chemotherapy for Chagas disease: 15 years of research contributions through in vivo and in vitro studies. Mem. Inst. Oswaldo Cruz, 2009, 104 (Suppl. I), 301-10.
14. Marin-Neto, J.A.; Rassi Jr, A.; Avezum Jr, A.; Mattos, A.C.; Rassi, A.; Morillo, C.A.; Sosa-Estani, S.; Yusuf, S. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem. Inst. Oswaldo Cruz, 2009, 104 (Suppl. I), 319-24.
15. Coura, J.R. Present situation and new strategies for Chagas disease chemotherapy - a proposal. Mem. Inst. Oswaldo Cruz, 2009, 104 (Suppl. I), 549-54.
16. Cancado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev. Inst. Med. Trop. São Paulo, 2002, 44, 29-37.
17. Viotti, R.; Vigliano, C.; Armenti, H.; Segura, E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am. Heart J., 1994, 127, 151-62.
18. Viotti, R.; Vigliano, C.; Lococo, B.; Bertocchi, G.; Petti, M.; Alvarez, M.G.; Postan, M.; Armenti, A. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med., 2006, 144, 724-34.
19. Viotti, R.; Vigliano, C.; Lococo, B.; Alvarez, M.G.; Petti, M.; Bertocchi, G.; Armenti, A. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti-Infect. Ther., 2009, 7, 157-63.
20. Viotti, R.; Vigliano, C. Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine. Expert Rev. Anti-Infect. Ther., 2007, 5, 717-26.
21. Fragata Filho, A.A.; Silva M.A.; Boainain, E. Ethiologic treatment of acute and chronic Chagas' disease. Sao Paulo Med. J., 1995, 113, 867-72.
22. Bahia-Oliveira, L.M.; Gomes, J.A.; Cançado, J.R.; Ferrari, T.C.; Lemos, E.M.; Luz, Z.M.; Moreira, M.C.; Gazzinelli, G.; Correa-Oliveira, R. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. J. Infect. Dis., 2000, 182, 634-8.
23. Fabbro De Suasnábar, D.; Arias, E.; Streiger, M.; Piacenza, M.; Ingaramo, M.; Del Barco, M.; Amicone, N. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev. Inst. Med. Trop. Sao Paulo, 2000, 42, 99-109.
24. Sosa-Estani, S.; Segura, E.L. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Curr. Opin. Infect. Dis., 2006, 19, 583-7.
25. Brener, Z.; Cançado, J.R.; Galvão, L.M.; Da Luz, Z.M.; Filardi, L.S.; Pereira, M.E.; Santos, L.M.; Cançado, C.B. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem. Inst. Oswaldo Cruz, 1993, 88, 149-53.
26. Apt, W.; Arribada, A.; Zulantay, I.; Solari, A.; Sánchez, G.; Mundaca, K.; Coronado, X.; Rodríguez, J.; Gil, L.C.; Osuna, A. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Ann. Trop. Med. Parasitol., 2005, 99, 733-41.
27. Soeiro MNC; De Castro SL. Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opin. Ther. Targets, 2009, 13, 105-21.
28. Blum, J.; Desjeux, P.; Schwartz, E.; Beck, B.; Hatz, C. Treatment of cutaneous leishmaniasis among travelers. J. Antimicrob. Chemother., 2004, 53, 158-66.
29. Wilson, W.D.; Tanious, F.A.; Mathis, A.; Tevis, D.; Hall, J.E.; Boykin, D.W. Antiparasitic compounds that target DNA. Biochimie, 2008, 90, 999-1014.
30. Werbovetz, K. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr. Opin. Investig, Drugs, 2006, 7, 147-57.
31. De Souza, E.M.; Lansiaux, A.; Bailly, C.; Wilson, W.D.; Hu, Q.; Boykin, D.W.; Batista, M.M.; Araújo-Jorge, T.C.; Soeiro, M.N.C. Phenyl substitution of furamidine markedly potentiates its antiparasitic activity against Trypanosoma cruzi and Leishmania amazonensis. Biochem. Pharmacol., 2004, 68, 593-600.
32. De Souza, E.M.; Melo, G.; Boykin, D.W.; Wilson, W.D.; Hu, Q.; Soeiro, M.N.C. Trypanocidal activity of the phenyl-substituted analogue of furamidine DB569 against Trypanosoma cruzi infection in vivo. J. Antimicrob. Chemoth., 2006, 58, 610-4.
33. De Souza, E.M.; Oliveira, G.M.; Soeiro, M.N.C. Electrocardiographic findings in acutely and chronically Trypansoma cruziinfected mice treated by a phenyl-substituted analogue of furamidine DB569. Drug Targets Insights, 2007, 2, 61-9.
34. Silva, C.F.; Batista, M.M.; Batista, D.G.; De Souza, E.M.; Silva, P.B.; Oliveira, G.M.; Batista, M.M.; Shareef, A.R.; Boykin, D.W.; Soeiro, M.N.C. In vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi. Antimicrob. Agents Chemother., 2008, 52, 3307-14.
35. Batista, D.G.J.; Pacheco, M.G.O.; Kumar, A.; Branowska, D.; Ismail, M.A.; Hu, L.; Boykin, D.W.; Soeiro, M.N.C. Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi. Parasitology, 2009, 21, 1-9.
36. Silva, C.F.; Batista, M.M.; Mota, R.A.; De Souza, E.M.; Stephens, C.E.; Som, P.; Boykin, D.W.; Soeiro, M.N.C. Activity of "reversed" diamidines against Trypanosoma cruzi in vitro. Biochem. Pharmacol., 2007a, 73, 1939-46.
37. Pacheco, M.G.O.; Silva, C.F.; De Souza, E.M.; Batista, M.M.; Silva, P.B.; Kumar, A.; Stephens, C.E.; Boykin, D.W.; Soeiro, M.N.C. Trypanosoma cruzi: Activity of heterocyclic cationic molecules in vitro. Exp. Parasitol., 2009, 123, 73-80.
38. Rosypal, A.C.; Hall, J.E.; Bakunova, S.; Patrick, D.A.; Bakunov, S.; Stephens, C.E.; Kumar, A.; Boykin, D.W.; Tidwell, R.R. In vitro activity of dicationic compounds against a North American foxhound isolate of Leishmania infantum. Vet. Parasitol., 2007, 145, 207-16.
39. Rosypal, A.C.; Werbovetz, K.A.; Salem, M.; Stephens, C.E.; Kumar, A.; Boykin, D.W.; Hall, J.E.; Tidwell, R.R. Inhibition by dications of in vitro growth of Leishmania major and Leishmania tropica: causative agents of old world cutaneous leishmaniasis. J. Parasitol., 2008, 94, 743-9.
40. Stephens, C.E.; Brun, R.; Salem, M.M.; Werbovetz, K.A.; Tanious, F.; Wilson, W.D.; Boykin, D.W. The activity of diguanidino and "reversed" diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania donovani. Bioorg. Med. Chem. Lett., 2003, 13, 2065-9.
41. Silva, C.F.; Batista, M.M.; De Souza, E.M.; Meirelles, M.N.L.; Stephens, C.E.; Som, P.; Boykin, D.W.; Soeiro, M.N.C. Cellular effects of reversed amidines on Trypanosoma cruzi. Antimicrob. Agents Chemother., 2007b, 51, 3803-9.
42. Carter, N.S.; Berger, B.J.; Fairlamb, A.H. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and - resistant Trypanosoma brucei brucei. J. Biol. Chem., 1995, 270, 28153-7.
43. Barrett, M.P.; Burchmore, R.J.; Stich, A.; Lazzari, J.O.; Frasch, A.C.; Cazzulo, J.J.; Krishna, S. The trypanosomiases. Lancet, 2003, 362, 1469-80.
44. Bray, P.G.; Barrett, M.P.; Ward, S.A.; de Koning, H.P. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol., 2003, 19, 232-39.
45. Daliry, A.; Bernadino, B.; Batista, M.M.; De Castro, S.L.; Tidwell, R.; Soeiro, M.N.C. In vitro analyses of the effect of aromatic diamidines upon Trypanosoma cruzi. J. Antimicrob. Agents, 2009, 64, 747-50.
46. Mathis, A.M.; Bridges, A.S.; Ismail, M.A.; Kumar, A.; Francesconi, I.; Anbazhagan, M.; Hu, Q.; Tanious, F.A.; Wenzler, T.; Saulter, J.; Wilson, W.D.; Brun, R.; Boykin, D.W.; Tidwell, R.R.; Hall, J.E. Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes Antimicrob. Agents Chemother., 2007, 51, 2801-10.
47. Souto-Padron, T.; Cunha-Silva, N.L.; De Souza, W. Acetylated α-tubulin in Trypanosoma cruzi: immunocytochemical localization. Mem. Inst. Oswaldo Cruz, 1993, 8, 517-28.
48. Dantas, A.P.; Barbosa, H.S.; De Castro, S.L. Biological and ultrastructural effects of the anti-microtubule agent taxol against Trypanosoma cruzi. J. Submicr. Cytol. Pathol., 2003, 35, 287-94.
49. Soeiro, M.N.C.; De Souza, E.M.; Stephens, C.E.; Boykin, D.W. Aromatic diamidines as antiparasitic agents. Expert Opin. Investig. Drugs, 2005, 14, 957-72.
50. Mathis, A.M.; Holman, J.L.; Sturk, L.M.; Ismail, M.A.; Boykin, D.W.; Tidwell, R.R.; Hall, J.E. Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrob. Agents Chemother., 2006, 50, 2185-91.
51. Singh, G.; Dey, C.S. Induction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant Leishmania donovani. Acta Trop., 2007, 103, 172-85.
52. Shapiro, T.A.; Englund, P.T. The structure and replication of kinetoplast DNA. Annu. Rev. Microbiol., 1995, 49, 117-43.
53. Dykstra, C.C.; McClernon, D.R.; Elwell, L.P.; Tidwell, R.R. Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells. Antimicrob. Agents Chemother., 1994, 38, 1890-8.
54. Soeiro, M.N.C.; De Castro, S.L.; De Souza, E.M.; Batista, D.G.J.; Silva, C.F.; Boykin, D.W. Diamidines activity upon trypanosomes: The state of the art. Curr. Mol. Pharmacol., 2008, 1, 151-61.
55. Monks, T.J.; Hanslik, R.P.; Cohen, G.M.; Ross, D.; Graham, D.G. Quinone chemistry and toxicity. Toxicol. Appl. Pharmacol., 1992, 112, 2-16.
56. Goulart, M.O.F.; Falkowski, P.; Ossowski, T.; Liwo, A. Electrochemical study of oxygen interaction with lapachol and its radical anions. Bioelectrochemistry, 2003, 59, 85-7.
57. Pinto, A.V.; De Castro, S.L. The trypanocidal activity of naphthoquinones: a review. Molecules, 2009, 14, 4570-90.
58. Boveris, A.; Docampo, R.; Turrens, J.F.; Stoppani A.O.M. Effect of β-lapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi. Biochem. J., 1978, 175, 431-9.
59. Cruz, F.S.; Docampo, R.; De Souza, W. Effect of β-lapachone on hydrogen peroxide production in Trypanosoma cruzi. Acta Trop., 1978, 35, 35-40.
60. Docampo, R.; Cruz, F.S.; Boveris, A.; Muniz, R.P.; Esquivel, D.M. Lipid peroxidation and the generation of free radicals, superoxide anion, and hydrogen peroxide in β-lapachone-treated Trypanosoma cruzi epimastigotes. Arch. Biochem. Biophys., 1978, 186, 292-7.
61. Goijman, S.G.; Stoppani A.O.M. Effects of β-lapachone, a peroxide-generating quinone, on macromolecule synthesis and degradation in Trypanosoma cruzi. Arch. Biochem. Biophys., 1985, 240, 273-80.
62. Molina-Portela, M.P.; Fernandez-Villamil, S.H.; Perissinotti, L.J.; Stoppani, A.O.M. Redox cycling of o-naphthoquinones in trypanosomatids. Superoxide and hydrogen peroxide production. Biochem. Pharmacol., 1996, 52, 1875-82.
63. Stoppani, A.O.M. The chemotherapy of Chagas disease. Medicina, 1999, 59, 147-65.
64. Docampo, R.; Lopes, J.N.; Cruz, F.S.; DeSouza W. Trypanosoma cruzi: ultrastructural and metabolic alterations of epimastigotes by β-lapachone. Exp. Parasitol., 1977, 42, 142-9.
65. Pinto, A.V.; Menna-Barreto, R.F.S.; De Castro, S.L. Naphthoquinones isolated from Tabebuia: a review about the synthesis of heterocyclic derivatives, screeening against Trypanosoma cruzi and correlation structure-trypanocidal activity. In Recent Progress in Medicinal Plants, Govil, J.N., Ed., Studium Press: Texas, 2006; Vol. 16, pp. 112-27.
66. Pinto, A.V.; Neves Pinto, C.; Pinto, M.C.F.R.; Santa-Rita, R.M.; Pezzella, C.; De Castro, S.L. (1997) Trypanocidal activity of synthetic heterocyclic derivatives from active quinones from Tabebuia sp. Arzneim-Forsch., 1997, 47 (I), 74-9.
67. Neves-Pinto, C.; Dantas, A.P.; Moura, K.C.G.; Emery, F.S.; Polequevitch, P.F.; Pinto, M.C.F.R.; De Castro, S.L.; Pinto, A.V. Chemical reactivity studies with naphthoquinones from Tabebuia with anti-trypanosomal efficacy. Arzneim-Forsch., 2000, 50(II), 1120-8.
68. Moura, K.C.G.; Emery, F.S.; Neves-Pinto, C.; Pinto, M.C.F.R.; Dantas, A.P.; Salomão, K.; De Castro, S.L.; Pinto, A.V. Synthesis and trypanocidal activity of naphthoquinones isolated from Tabebuia and heterocyclic derivatives: A review from an interdisciplinary study. J. Braz. Chem. Soc., 2001, 12, 325-38.
69. Moura, K.C.G.; Salomão, K.; Menna-Barreto, R.F.S.; Emery, F.S.; Pinto, M.C.F.R.; Pinto, A.V.; De Castro, S.L. Studies on the trypanocidal activity of semi-synthetic pyran[b-4,3]naphtho[1,2-d]imidazoles from β-lapachone. Eur. J. Med. Chem., 2004, 39, 639-45.
70. Menna-Barreto, R.F.S.; Henriques-Pons, A.; Pinto, A.V.; Morgado-Diaz, J.A.; Soares, M.J.; De Castro, S.L. Effect of a β-lapachonederived naphthoimidazole on Trypanosoma cruzi: Identification of target organelles. J. Antimicrob. Chemother., 2005, 56, 1035-41.
71. Menna-Barreto, R.F.S.; Corrêa, J.R.; Pinto, A.V.; Soares, M.J.; De Castro, S.L. Mitochondrial disruption and DNA fragmentation in Trypanosoma cruzi induced by naphthoimidazoles synthesized from β-lapachone. Parasitol. Res., 2007, 101, 895-905.
72. Menna-Barreto, R.F.S.; Salomão, K.; Dantas, A.P.; Santa-Rita, R.M.; Soares, M.J.; Barbosa, H.S.; De Castro, S.L. Different cell death pathways induced by drugs in Trypanosoma cruzi: an ultrastructural study. Micron, 2009a, 40, 157-68.
73. Menna-Barreto, R.F.S.; Corrêa, J.R.; Cascabulho, C.M.; Fernandes, M.C.; Pinto, A.V.; Soares, M.J.; De Castro, S.L. Naphthoimidazoles promote different death phenotypes in Trypanosoma cruzi. Parasitology, 2009b,136, 499-510.
74. Winkelmann, E.; Raether, W. Sinharay, A. Chemotherapeutically active nitro compounds. 4,5-Nitroimidazoles (Part II). Arzneim- Forsch., 1978, 28, 351-66.
75. Chabala, J.C.; WQaits, V.B.; Ikeler, T.; Patchett, A.A.; Payne, L.; Peterson, L.H.; Reamer, R.A.; Hoogsteen, K.; Wyvratt, M.; Hanson, W.L.; Fisher, M.H. 1-(substituted)benzyl-5-aminiimidazole-4-carboxamides are potent orally active inhibitors of Trypanosoma cruzi in mice. Experientia, 1991, 47, 51-3.
76. Nothemberg, M.S.; Takeda, G.K.F.; Najjar, R. Adducts of nitroimidazole derivatives with Rhodium(II) carboxylates: Synthesis, characterization and evaluation of antichagasic activities. J. Inorg. Biochem., 1991, 42, 217-29.
77. Da Silva Jr, E.M.; Menna-Barreto, R.F.S.; Pinto, M.C.F.R.; Silva, R.S.F.; Teixeira, D.V.; Souza, M.C.B.V.; De Simone, C.A.; De Castro, S.L.; Ferreira, V.F.; Pinto, A.V. Naphthoquinoidal [1,2,3]-triazole, a new structural moiety active against Trypanosoma cruzi. Eur. J. Med. Chem., 2008a, 43, 1774-80.
78. Da Silva Jr, E.M.; Souza, M.C.B.V.; Fernandes, M.C.; Menna-Barreto, R.F.S.; Pinto, M.C.F.R.; Lopes, F.A.; De Simone, C.A.; Andrade, C.K.; Pinto, A.V.; Ferreira, V.F.; De Castro, S.L. Synthesis and anti-Trypanosoma cruzi activity of derivatives from norlapachones and lapachones. Bioorganic. Med. Lett., 2008b, 16, 5030-8.
79. Silva, R.S.F.; Costa, E.M.; Trindade, U.L.T.; Teixeira, D.V.; Pinto, M.C.F.R.; Santos, G.L.; Malta, V.R.S.; De Simone, C.A.; Pinto, A.V.; De Castro, S.L. Synthesis of naphthofuranquinones with activity against Trypanosoma cruzi. Eur. J. Med. Chem., 2006, 41, 526-30.
80. Menna-Barreto, R.F.S.; Gonçalves, R.L.S.; Costa, M.; Silva, R.S.F.; Pinto, A.V.; Oliveira, M.F.; De Castro, S.L. The activity against Trypanosoma cruzi of novel synthetic naphthoquinones is mediated by mitochondrial dysfunction and oxidative stress. Free Rad. Biol. Med., 2009c, 47, 644-53.
81. Lages-Silva, E.; Filardi, L.S.; Brener, Z. Effect of the host specific treatment in the phagocytosis of Trypanosoma cruzi blood forms by mouse peritoneal macrophages. Mem. Inst. Oswaldo Cruz, 1990, 85, 401-5.
82. Filardi, L.S.; Brener, Z. A nitroimidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infections. Ann. Trop. Med. Parasitol., 1982, 76, 293-7.
83. De Castro, S.L.; Meirelles, M.N.L. Effect of drugs on Trypanosoma cruzi and on its interaction with heart muscle cell in vitro. Mem. Inst. Oswaldo Cruz, 1987, 82, 209-18.
84. De Castro, S.L.; Meirelles, M.N.L. Mechanism of action of a nitroimidazole-thiadiazole derivative upon Trypanosoma cruzi tissue culture amastigotes. Mem. Inst. Oswaldo Cruz, 1990, 85, 95-9.
85. Viode, C.; Bettache, N.; Cenas, N.; Krauth-Siegel, R.L.; Chauvière, G.; Bakalara, N.; Périé, J. Enzymatic reduction studies of nitroheterocycles. Biochem. Pharmacol., 1999, 57, 549-57.
86. Maya, J.D.; Bollo, S.; Nunez-Vergara, L.J.; Squella, J.A.; Repetto, Y.; Morello, A.; Périé, J.; Chauvière, G. Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem. Pharmacol., 2003, 65, 999-1006.
87. Ferreira, R.C.; Ferreira, L.C. Mutagenicity of CL 64855, a potent anti-Trypanosoma cruzi drug. Mutat. Res., 1986, 171, 11-5.
88. Poli, P.; Mello, M.A.; Buschini, A.; Mortara, R.A.; Albuquerque, C.; Silva, S.; Rossi, C.; Zucchi, T.M. Cytotoxic and genotoxic effects of megazol, an anti-Chagas disease drug, assessed by different short-term tests. Biochem. Pharmacol., 2002, 64, 1617-27.
89. Nesslany, F.; Brugier, S.; Mouries, M.A.; Le, C.F.; Marzin, D. In vitro and in vivo chromosomal aberrations induced by megazol. Mutat. Res., 2004, 560, 147-58.
90. Bouteille, B.; Marie-Daragon, A.; Chauvière, G.; Albuquerque, C.; Enanga, B.; Darde, M.L.; Vallat, J.M.; Périé, J.; Dumas, M. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice. Acta Trop., 1995, 60, 73-80.
91. Barrett, M.P.; Fairlamb, A.H.; Rousseau, B.; Chauvière, G.; Perié, J. Uptake of the nitroimidazole drug megazol by African trypanosomes. Biochem. Pharmacol., 2000, 59, 615-20.
92. Boechat, N.; Carvalho, A.S.; Fernandez-Ferreira, E.; Soares, R.O.; Souza, A.S.; Gibaldi, D.; Bozza, M.; Pinto, A.C. Novel nitroimidazoles with trypanocidal and cell growth inhibition activities. Cytobios, 2001, 105, 83-90.
93. Chauvière, G.; Bouteille, B.; Enanga, B.; Albuquerque, C.; Croft, S.L.; Dumas, M.; Périé, J. Synthesis and biological activity of nitro heterocycles analogs to megazol, a trypanocidal lead. J. Med. Chem., 2003, 46, 427-40.
94. Carvalho, A.S.; Menna-Barreto, R.F.S.; Romeiro, M.C.; De Castro, S.L.; Boechat, N. Design, synthesis and activity against Trypanosoma cruzi of azaheterocyclic analogues of megazol. Med. Chem., 2007, 3, 460-5.
95. Carvalho, S.A.; Silva, E.F.; Santa-Rita, R.M.; De Castro, S.L.; Fraga, C.A.M. Synthesis and antitrypanosomal profile of new functionalyzed 1,3,4-thiadiazole-2-arylhydrazone derivatives, designed as non-mutagenic megazol analogues. Bioorg. Med. Chem. Lett., 2004, 14, 5967-70.
96. Carvalho, S.A.; Lopes, F.A.S.; Salomão, K.; Romeiro, N.C.; Wardell, S.M.V.S.; De Castro, S.L.; Silva, E.F.; Fraga, C.A.M. Studies toward the structural optimization of new Brazilizonerelated trypanocidal 1,3,4-thiadiazole-2-arylhydrazone derivatives. Bioorg. Med. Chem., 2008, 16, 413-21.
97. Mahy, J.P.; Gaspard, S.; Mansuy, D. Phenylhydrazones as new good substrates for the dioxygenase and peroxidase reactions of prostaglandin synthase: formation of iron(III)-sigma-phenyl complexes. Biochemistry, 1993, 32, 4014-21.
98. Prusis, P.; Dambrova, M.; Andrianov, V.; Rozhkov, E.; Semenikhina, V.; Piskunova, I.; Ongwae, E.; Lundstedt, T.; Kalvinsh, I.; Wikberg, J.E. Synthesis and quantitative structure-activity relationship of hydrazones of N-amino-Ń-hydroxyguanidine as electron acceptors for xanthine oxidase. J. Med. Chem., 2004, 47, 3105-10.
99. Messeder, J.C.; Tinoco, W.; Figueroa-Villar, J.D.; De Souza, E.M.; Santa-Rita, R.M.; De Castro, S.L. Aromatic guanylhydrazones: Synthesis, structural studies and in vitro activity against Trypanosoma cruzi. Bioorg., Med. Chem. Lett., 1995, 24, 3079-84.
100. Cerecetto, H.; Di Maio, R.; González, M.; Risso, M.; Sagrera, G.; Seoane, G.; Denicola, A.; Peluffo, G.; Quijano, C.; Stoppani, A.O.M.; Paulino, M.; Olea-Azar, C.; Basombrío, M.A. Synthesis and antitrypanosomal evaluation of E-isomers of 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives. Structure-activity relationships. Eur. J. Med. Chem., 2000, 35, 343-50.
101. Du, X.; Guo, C.; Hansell, E.; Doyle, P.S.; Caffrey, C.R.; Holler, T.P.; McKerrow, J.H.; Cohen, F.E. Synthesis and structure-activity relationship study of potent trypanocidal thiosemicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem., 2002, 45, 2695-707.
102. Aguirre, G.; Bolani, M.; Cerecetto, H.; Gerpe, A.; Gonzalez, M.; Sainz, Y.F.; Denicola, A.; Ocariz, C.O.; Nogal, J.J.; Montero, D.; Escario, J.A. Novel antiprotozoal products: Imidazole and benzimidazole N-oxide derivatives and related compounds. Arch. Pharm., 2004, 337, 259-70.
103. Salomão, K.; De Souza, E.M.; Carvalho, A.S.; Silva, E.F.; Fraga, C.A.M.; Barbosa, H.S.; De Castro, S.L. In vitro and in vivo activity of 1,3,4-thiadiazole-2-arylhydrazone derivatives of megazol on Trypanosoma cruzi. Antimicrob. Agent Chemother., 2010, 54, 2023-31.
104. Romanha, A.J.; De Castro, S.L.; Soeiro, M.N.C.; Lannes-Vieira, J.; Ribeiro, I.; Talvani, A.; Bourdin, B.; Blum, B.; Olivieri, B.; Zani, C.; Spadafora, C.; Chiari, E.; Chatelain, E.; Chaves, G.; Calzada, J.E.; Bustamante, J.M.; Freitas Jr., L.; Romero, L.I.; Bahia, M.T.; Lotrowska, M.; Soares, M.; Andrade, S.G.; Armstrong, T.; Degrave, W.; Andrade, Z.A. In vitro and in vivo experimental models to drug screening and development for Chagas disease "PIDC/Fiocruz & DNDi Meeting, November 2008, Rio de Janeiro, Mem. Inst. Oswaldo Cruz, 2010, 105, 233-8.
105. Oliveira Jr, W. All-around care for patients with Chagas disease: a challenge for the XXI century. Mem. Inst. Oswaldo Cruz, 2009, 104 (Suppl. I), 181-6.